Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients

Inclusion Criteria:

1. Histologically confirmed acute myeloid leukemia (non-M3) that has not beenpreviously treated and cannot receive standard cytarabine and anthracyclineinduction therapy due to age, comorbidities, or patient preference.

2. Aged 60-75 years, both male and female, with an expected survival time of more than 3 months.

3. Estimated creatinine clearance rate ≥ 30 mL/min.

4. AST and ALT ≤ 3.0 x ULN (unless considered due to leukemic organ involvement).Bilirubin ≤ 1.5 x ULN (unless considered due to leukemic organ involvement).

5. ECOG Performance Status ≤ 2.

6. Able to understand and voluntarily provide informed consent.

Exclusion Criteria:

1. Acute promyelocytic leukemia (APL) and low-risk cytogenetics, such as t(8;21),inv(16), or t(16;16).

2. Active central nervous system leukemia.

3. History of myeloproliferative neoplasms (MPN), including myelofibrosis, primarythrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or withoutBCR-ABL1 translocation, and AML with BCR-ABL1 translocation.

4. HIV-positive patients and/or active HBV or HCV infection (as documented by positiveHBV-DNA and HCV-RNA tests).

5. Clinically significant QTc prolongation (men > 450 ms; women > 470 ms), ventriculartachycardia, atrial fibrillation, second-degree heart block, history of myocardialinfarction within the past year, congestive heart failure, and coronary arterydisease requiring medication.

6. Active, uncontrolled severe infection.

7. History of other malignancies within the past 2 years, except for adequately treatedin situ carcinoma of the cervix or breast; skin basal cell carcinoma or localizedsquamous cell carcinoma of the skin.

8. White blood cell count > 25 x 10^9/L. (This criterion can be met with hydroxyurea orleukapheresis.)

9. Mental impairment that would compromise the ability to participate in the study.

10. Any other situation in which the investigator believes that it would not be in thebest interest of the patient to participate in the trial.